{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:51:53Z","timestamp":1788850313749,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key research and development plan","award":["2022YFC3501303"],"award-info":[{"award-number":["2022YFC3501303"]}]},{"name":"National Key research and development plan","award":["2022YFC3501305"],"award-info":[{"award-number":["2022YFC3501305"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071410"],"award-info":[{"award-number":["82071410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001335"],"award-info":[{"award-number":["82001335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies primarily affecting the neuromuscular junction. This study aims to identify risk factors for pregnancy-related MG relapse and develop a predictive model to improve clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We enrolled 113 MG female patients with a pregnancy history during follow-up at Huashan Hospital affiliated with Fudan University, between January 2015 and October 2021. The study analyzed relapse rates and risk factors during pregnancy and postpartum using multivariate logistic regression. A nomogram was constructed to predict relapse probability, with model performance evaluated by discrimination and calibration metrics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 113 patients, 52 (46.02%) experienced 115 relapses, including 52 (45.22%) occurring during the first trimester of pregnancy, 11 (9.56%) during the second trimester of pregnancy, and 52 relapses (45.22%) during the three months after delivery\/abortion. Significant factors associated with pregnancy-relate relapse, included age at delivery\/abortion (OR 0.21, 95% CI 0.06\u20130.65), MG stable duration (OR 0.24, 95% CI 0.09\u20130.63), thymic hyperplasia (OR 3.45, 95% CI 1.35\u20139.3), pre-pregnancy thymectomy (OR 0.08, 95% CI 0.01\u20130.36), and inadequate treatment during pregnancy (OR 4.44, 95% CI 1.35\u201317.76). The Nomogram model demonstrated robust predictive performance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The first trimester of pregnancy and three months following delivery or abortion are high-risk periods for MG relapse. Younger ages, shorter MG stable duration before pregnancy, thymic hyperplasia, and inadequate treatments during pregnancy increase relapse risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03466-6","type":"journal-article","created":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T15:28:01Z","timestamp":1733066881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nomogram for predicting pregnancy-related relapse of myasthenia gravis"],"prefix":"10.1186","volume":"19","author":[{"given":"Manqiqige","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongtai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9033-7568","authenticated-orcid":false,"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"issue":"5","key":"3466_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390.","journal-title":"Lancet Neurol"},{"issue":"11","key":"3466_CR2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"key":"3466_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/ane.12233","volume":"198","author":"JB Andersen","year":"2014","unstructured":"Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl. 2014;198:26\u201331.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3466_CR4","first-page":"100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian DC, Zhang C, Li Z, Zhai Y, Xiu Y, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063.","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"3466_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mus.27331","volume":"64","author":"JLS Thomsen","year":"2021","unstructured":"Thomsen JLS, Vinge L, Harbo T, Andersen H. Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve. 2021;64(5):538\u201344.","journal-title":"Muscle Nerve"},{"key":"3466_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"key":"3466_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1590\/S0004-282X1999000300018","volume":"57","author":"FM Cunha","year":"1999","unstructured":"Cunha FM, Scola RH. Werneck LC [Myasthenia gravis. Clinical evaluation of 153 patients]. Arq Neuropsiquiatr. 1999;57:457\u201364.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"3466_CR8","first-page":"e6808","volume":"12","author":"OJ Hernandez Fustes","year":"2020","unstructured":"Hernandez Fustes OJ, Arteaga Rodriguez C, Hernandez Fustes OJ. Myasthenia gravis with elderly onset at advanced age. Cureus. 2020;12(1):e6808.","journal-title":"Cureus"},{"issue":"6","key":"3466_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/mus.27064","volume":"62","author":"KM Grover","year":"2020","unstructured":"Grover KM, Sripathi N. Myasthenia gravis and pregnancy. Muscle Nerve. 2020;62(6):664\u201372.","journal-title":"Muscle Nerve"},{"issue":"4","key":"3466_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nmd.2017.01.021","volume":"27","author":"RD Ducci","year":"2017","unstructured":"Ducci RD, Lorenzoni PJ, Kay CS, Werneck LC, Scola RH. Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscul Disord. 2017;27(4):352\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3466_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13023-022-02205-z","volume":"17","author":"M Su","year":"2022","unstructured":"Su M, Liu X, Wang L, Song J, Zhou Z, Luo S, et al. Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis. Orphanet J Rare Dis. 2022;17(1):52.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3466_CR12","doi-asserted-by":"publisher","first-page":"e13641","DOI":"10.1111\/aji.13641","volume":"88","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Yin W, Zhu J, Duan W, Li Y, Jin W, et al. Risk factors associated with adverse pregnancy outcomes and postpartum exacerbation in women with myasthenia gravis. Am J Reprod Immunol. 2022;88(6):e13641.","journal-title":"Am J Reprod Immunol"},{"issue":"6","key":"3466_CR13","first-page":"767","volume":"48","author":"M Alharbi","year":"2021","unstructured":"Alharbi M, Menon D, Barnett C, Katzberg H, Sermer M, Bril V. Myasthenia gravis and pregnancy: toronto specialty center experience. Can J Neurol Sci. 2021;48(6):767\u201371.","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"3466_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"6","key":"3466_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630\u20139.","journal-title":"Muscle Nerve"},{"issue":"8","key":"3466_CR16","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/jcm11082189","volume":"11","author":"L Diez Porras","year":"2022","unstructured":"Diez Porras L, Homedes C, Alberti MA, Velez Santamaria V, Casasnovas C. Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med. 2022;11(8):2189.","journal-title":"J Clin Med"},{"key":"3466_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","volume":"85","author":"F Norwood","year":"2014","unstructured":"Norwood F, Dhanjal M, Hill M, James N, Jungbluth H, Kyle P, et al. Myasthenia in pregnancy: best practice guidelines from a UK. multispecialty working group. J Neurol Neurosurg Psychiatry. 2014;85:538\u201343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 3","key":"3466_CR18","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1016\/S0020-7292(15)30007-2","volume":"131","author":"M Hod","year":"2015","unstructured":"Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015;131(Suppl 3):S173-211.","journal-title":"Int J Gynaecol Obstet"},{"key":"3466_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40200-015-0169-7","volume":"14","author":"BC Mpondo","year":"2015","unstructured":"Mpondo BC, Ernest A, Dee HE. Gestational diabetes mellitus: challenges in diagnosis and management. J Diabetes Metab Disord. 2015;14:42.","journal-title":"J Diabetes Metab Disord"},{"issue":"2","key":"3466_CR20","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1161\/HYP.0000000000000208","volume":"79","author":"VD Garovic","year":"2022","unstructured":"Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the american heart association. Hypertension. 2022;79(2):e21\u201341.","journal-title":"Hypertension"},{"issue":"20","key":"3466_CR21","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/WNL.0000000000003339","volume":"87","author":"MI Boldingh","year":"2016","unstructured":"Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekjaer H, Verschuuren JJ, Tallaksen CM. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology. 2016;87(20):2139\u201345.","journal-title":"Neurology"},{"issue":"4","key":"3466_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1095\/biolreprod.109.081208","volume":"82","author":"J Mjosberg","year":"2010","unstructured":"Mjosberg J, Berg G, Jenmalm MC, Ernerudh J. FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol Reprod. 2010;82(4):698\u2013705.","journal-title":"Biol Reprod"},{"issue":"3","key":"3466_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366\u201374.","journal-title":"Clin Exp Immunol"},{"key":"3466_CR24","doi-asserted-by":"publisher","first-page":"102651","DOI":"10.1016\/j.jaut.2021.102651","volume":"121","author":"JJ Graham","year":"2021","unstructured":"Graham JJ, Longhi MS, Heneghan MA. T helper cell immunity in pregnancy and influence on autoimmune disease progression. J Autoimmun. 2021;121:102651.","journal-title":"J Autoimmun"},{"key":"3466_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fendo.2014.00039","volume":"5","author":"D Muzzio","year":"2014","unstructured":"Muzzio D, Zygmunt M, Jensen F. The role of pregnancy-associated hormones in the development and function of regulatory B cells. Front Endocrinol (Lausanne). 2014;5:39.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"3466_CR26","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1073\/pnas.77.6.3635","volume":"77","author":"T Brenner","year":"1980","unstructured":"Brenner T, Beyth Y, Abramsky O. Inhibitory effect of alpha-fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor. Proc Natl Acad Sci U S A. 1980;77(6):3635\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3466_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99\u2013105.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"3466_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/mus.25095","volume":"54","author":"AC Braga","year":"2016","unstructured":"Braga AC, Pinto C, Santos E, Braga J. Myasthenia gravis in pregnancy: experience of a portuguese center. Muscle Nerve. 2016;54(4):715\u201320.","journal-title":"Muscle Nerve"},{"issue":"2","key":"3466_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41584-022-00883-4","volume":"19","author":"V Di Martino","year":"2023","unstructured":"Di Martino V, Verhoeven DW, Verhoeven F, Aubin F, Avouac J, Vuitton L, et al. Busting the myth of methotrexate chronic hepatotoxicity. Nat Rev Rheumatol. 2023;19(2):96\u2013110.","journal-title":"Nat Rev Rheumatol"},{"key":"3466_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/fneur.2020.00554","volume":"11","author":"NE Gilhus","year":"2020","unstructured":"Gilhus NE. Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol. 2020;11:554.","journal-title":"Front Neurol"},{"key":"3466_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13023-015-0332-8","volume":"10","author":"C Leroy","year":"2015","unstructured":"Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3466_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","volume":"43","author":"G Bandoli","year":"2017","unstructured":"Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43(3):489\u2013502.","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"3466_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ncl.2018.01.005","volume":"36","author":"J Hamel","year":"2018","unstructured":"Hamel J, Ciafaloni E. An update: myasthenia gravis and pregnancy. Neurol Clin. 2018;36(2):355\u201365.","journal-title":"Neurol Clin"},{"issue":"8","key":"3466_CR34","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/eji.201646309","volume":"46","author":"M Laan","year":"2016","unstructured":"Laan M, Haljasorg U, Kisand K, Salumets A, Peterson P. Pregnancy-induced thymic involution is associated with suppression of chemokines essential for T-lymphoid progenitor homing. Eur J Immunol. 2016;46(8):2008\u201317.","journal-title":"Eur J Immunol"},{"issue":"20","key":"3466_CR35","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMc1611704","volume":"375","author":"JB Shrager","year":"2016","unstructured":"Shrager JB. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(20):2005\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"3466_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03466-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03466-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03466-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T16:02:06Z","timestamp":1733068926000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03466-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3466"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03466-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by Huashan Hospital. The study was approved by the Medical Ethics Committee of Huashan Hospital (KY2019-441). Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from patients for publication of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any financial or non-financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}